Trial Profile
PLX R18 cells in aplastic anaemia.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Apr 2023
Price :
$35
*
At a glance
- Drugs Avoplacel (Primary)
- Indications Aplastic anaemia
- Focus Therapeutic Use
- 13 Mar 2023 According to a Pluristem Therapeutics media release, Pluristem Therapeutics has changed its name to Pluri Inc.
- 21 Apr 2015 New trial record